{"a":[{"_":"CEO O’Day tells Fierce how Gilead’s cancer, inflammation expansion has reached ‘critical mass’","$":{"href":"/biotech/its-cancer-and-inflammation-expansion-critical-mass-gileads-oday-eyes-companys-next-chapter","hreflang":"en"}}]}

Summary

Gilead CEO Daniel O'Day stated that the company has reached 'critical mass' in its cancer and inflammation expansion following three biotech acquisitions earlier in 2026. The company continues to diversify beyond its traditional antiviral portfolio.